diluted earnings per share and the related disclosure for Vaughn's financial statements. Below is selected financial information for the mpany, is currently preparing the calculation for basic and fiscal year ended June 30, 2025. Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt Vaughn Pharmaceutical Industries Selected Balance Sheet Information June 30, 2025 Shareholders' equity Preferred stock, 6% cumulative, $50 par value, 103,000 shares authorized, 25,750 shares issued and outstanding Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding Additional paid-in capital Retained earnings Total shareholders' equity $990,000 4,920,000 6,000,000 $11,910,000 $1,287,500 980,000 3,970,000 6,010,000 $12,247,500

diluted earnings per share and the related disclosure for Vaughin's financial statements. Below is selected financial information for the fiscal year ended June 30,2025 . The following transactions have also occurred at Vaughn. 1. Options were granted on July 1,2024, to purchase 210,000 shares at 516 per share. Although no options were exercised during fiscal year 2025, the average price per common share during fiscal year 2025 was $20 per share. 2. Each bond was issued at face value. The 9 siconvertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2024 , 3. The preferred stock was issued in 2024 4. There are no preferred dividends in arrears however, preferred dividends were not declared in fiscal year 2025. 5. The 980,000 shares of common stock were outstanding for the entire 2025 fiscal year, 6. Net income for fiscal year 2025 was $1,480,000, and the average income tax rate is 20% For the fiscal year ended Jone 30,2025, calculate the following for Vaughn Pharmsceutical Industries, (Round answers to 2 decimal places, eg. 2.45. a. Basic earnines per share. Basicearnings per share b. Diluted pacnings oer ahare. Diluted earninesper share